BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis 2016;22:1999-2015. [PMID: 27135483 DOI: 10.1097/MIB.0000000000000772] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Bjørlykke KH, Jahnsen J, Brynskov J, Molander P, Eberhardson M, Davidsdottir LG, Sipponen T, Hjortswang H, Goll GL, Syversen SW, Langholz E, Jørgensen KK, Steenholdt C. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scand J Gastroenterol 2023;58:25-33. [PMID: 35996928 DOI: 10.1080/00365521.2022.2108684] [Reference Citation Analysis]
2 Ben-shatach Z, Ziv-baran T, Fudim E, Yavzori M, Picard O, Levartovsky A, Selinger L, Weiss B, Kopylov U, Eliakim R, Ungar B. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therap Adv Gastroenterol 2022;15:175628482210833. [DOI: 10.1177/17562848221083395] [Reference Citation Analysis]
3 Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. Scand J Gastroenterol 2022;57:274-81. [PMID: 34779308 DOI: 10.1080/00365521.2021.2002397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Shehab M, Alasfour H, Abdullah I, Alhendi G, Alhadab A, Alfadhli A, Ziyab AH, Battat R. Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study. Front Med 2021;8. [DOI: 10.3389/fmed.2021.801532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Walshe M, Borowski K, Boland K, Rho S, Stempak JM, Silverberg MS. Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:e401-6. [PMID: 33731595 DOI: 10.1097/MEG.0000000000002116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Falsey A, Jo D, Sirak H, Moya D, Leibowitz IH, Yang J, Hourigan SK, May E. Corticosteroids Can Be Used to Decrease Antidrug Antibodies in Pediatric Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:e159-60. [PMID: 34319399 DOI: 10.1093/ibd/izab182] [Reference Citation Analysis]
7 Abdullah I, Alhendi G, Alhadab A, Alasfour H, Shehab M. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725512. [PMID: 34660635 DOI: 10.3389/fmed.2021.725512] [Reference Citation Analysis]
8 Guerin C Jr, Beylot-Barry M, Frouin E, Hainaut E, Masson Regnault M. Treatment of Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease) With Anti-Tumor Necrosis Factor Alpha. Cureus 2021;13:e17147. [PMID: 34532181 DOI: 10.7759/cureus.17147] [Reference Citation Analysis]
9 Beeg M, Burti C, Allocati E, Ciafardini C, Banzi R, Nobili A, Caprioli F, Garattini S, Gobbi M. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera. Sci Rep 2021;11:14976. [PMID: 34294782 DOI: 10.1038/s41598-021-94431-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shehab M, Alasfour H, Abdullah I, Alhendi G, Alhadab A, Alfadhli A, Ziyab AH, Battat R. Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study.. [DOI: 10.1101/2021.06.01.21258121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A. Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. Am J Clin Dermatol 2021;22:275-83. [PMID: 33242185 DOI: 10.1007/s40257-020-00575-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Grišić AM, Dorn-Rasmussen M, Ungar B, Brynskov J, Ilvemark JFKF, Bolstad N, Warren DJ, Ainsworth MA, Huisinga W, Ben-Horin S, Kloft C, Steenholdt C. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterol J 2021;9:91-101. [PMID: 33079627 DOI: 10.1177/2050640620964619] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Svoboda P, Kupka T. Infliximab pharmacokinetics monitoring in inflammatory bowel disease. Vnitr Lek 2020;66:e34-e38. [DOI: 10.36290/vnl.2020.156] [Reference Citation Analysis]
15 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
16 Assa A, Dorfman L, Shouval DS, Shamir R, Cohen S. Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series. J Pediatr Gastroenterol Nutr 2020;71:516-20. [PMID: 32639454 DOI: 10.1097/MPG.0000000000002832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scand J Gastroenterol 2020;55:920-3. [PMID: 32689833 DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Powell Doherty RD, Liao H, Satsangi JJ, Ternette N. Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab. Gastroenterology 2020;159:784-7. [PMID: 32275970 DOI: 10.1053/j.gastro.2020.03.073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Scheffe N, Schreiner R, Thomann A, Findeisen P. Development of a Mass Spectrometry-Based Method for Quantification of Ustekinumab in Serum Specimens. Therapeutic Drug Monitoring 2020;42:572-577. [DOI: 10.1097/ftd.0000000000000734] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scand J Gastroenterol 2020;55:884-90. [PMID: 32631131 DOI: 10.1080/00365521.2020.1786852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Colman RJ, Portocarrero-Castillo A, Chona D, Hellmann J, Minar P, Rosen MJ. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:507-15. [PMID: 32426829 DOI: 10.1093/ibd/izaa108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Ganesananthan S, Durai D. Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease. Clin Med (Lond) 2020;20:s23-4. [PMID: 32409349 DOI: 10.7861/clinmed.20-2-s23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [PMID: 31961001 DOI: 10.1111/apt.15643] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
24 Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials 2020;21:13. [PMID: 31907007 DOI: 10.1186/s13063-019-3734-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
25 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
26 Schoenefuss F, Hoffmann P. Serum γ-globulin and albumin concentrations predict secondary loss of response to anti-TNFα in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2019;31:1563-8. [PMID: 31567711 DOI: 10.1097/MEG.0000000000001493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
29 Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, Dipasquale V, Paci M, Zuin G, Aloi M, Strisciuglio C, Miele E, Pastore M, Martelossi S, Alvisi P; SIGENP IBD Working Group. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J 2019;7:759-66. [PMID: 31316780 DOI: 10.1177/2050640619847592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
30 Rocha C, Afonso J, Lago P, Arroja B, Vieira AI, Dias CC, Magro F. Accuracy of the new rapid test for monitoring adalimumab levels. Therap Adv Gastroenterol 2019;12:1756284819828238. [PMID: 30833984 DOI: 10.1177/1756284819828238] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
31 Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Eur J Gastroenterol Hepatol 2019;31:187-91. [PMID: 30543573 DOI: 10.1097/MEG.0000000000001332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
32 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis 2019;13:189-97. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
33 Srinivasan A, Ding NS, van Langenberg D, De Cruz P. Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_20] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Messaris E, Dassopoulos T. Concepts in Inflammatory Bowel Disease Management. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00161-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T. Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res 2019;17:94-106. [PMID: 30508475 DOI: 10.5217/ir.2018.00048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Buhl S, Kristina Borghede M, Brynskov J, Steenholdt C, Rasmussen M, Andrew Ainsworth M. Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study. Scand J Gastroenterol 2018;53:930-7. [PMID: 29987951 DOI: 10.1080/00365521.2018.1481519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Kanis SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, van der Woude CJ. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. J Crohns Colitis 2018;12:939-47. [PMID: 29771301 DOI: 10.1093/ecco-jcc/jjy058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
38 Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018;63:1583-91. [PMID: 29564674 DOI: 10.1007/s10620-018-5020-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
39 Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
40 Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.Therap Adv Gastroenterol. 2018;11:1756284818772786. [PMID: 29774052 DOI: 10.1177/1756284818772786] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
41 Steenholdt C. Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive. Clin Gastroenterol Hepatol 2018;16:597-8. [PMID: 29555230 DOI: 10.1016/j.cgh.2017.11.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Carlsen A, Omdal R, Leitao KØ, Isaksen K, Hetta AK, Karlsen LN, Aabakken L, Bolstad N, Warren D, Lundin KEA, Grimstad T. Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818759930. [PMID: 29623105 DOI: 10.1177/1756284818759930] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
43 Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis 2018;12:298-305. [PMID: 29145599 DOI: 10.1093/ecco-jcc/jjx149] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
44 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 177] [Cited by in F6Publishing: 135] [Article Influence: 29.5] [Reference Citation Analysis]
45 Nakase H. Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said? Author's reply. Aliment Pharmacol Ther 2017;46:1114-5. [PMID: 29105132 DOI: 10.1111/apt.14365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, Araki M, Hiyama S, Inoue T, Hayashi Y, Watabe K, Iijima H, Takehara T. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:2172-9. [PMID: 28945638 DOI: 10.1097/MIB.0000000000001260] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
47 Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2017;49:1086-91. [PMID: 28826571 DOI: 10.1016/j.dld.2017.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
48 Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, Arias L, Martínez-Montiel P, Juan A, Iglesias E, Algaba A, Manceñido N, Rivero M, Barreiro-de Acosta M, López-Serrano P, Argüelles-Arias F, Gutierrez A, Busquets D, Gisbert JP, Olivares D, Calvo M, Alba C; Collaborators. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2017;23:1394-402. [PMID: 28671873 DOI: 10.1097/MIB.0000000000001144] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
49 Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. [PMID: 28481014 DOI: 10.1111/apt.14124] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
50 Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1210-7. [PMID: 28445244 DOI: 10.1097/MIB.0000000000001117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
51 Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One 2017;12:e0175099. [PMID: 28426675 DOI: 10.1371/journal.pone.0175099] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
52 Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 2017;45:1135-45. [PMID: 28239869 DOI: 10.1111/apt.13992] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
53 Bendtzen K, Steenholdt C. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Aliment Pharmacol Ther 2017;45:759-60. [PMID: 28150453 DOI: 10.1111/apt.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
55 Boyapati RK, Kalla R, Satsangi J, Ho GT. Biomarkers in Search of Precision Medicine in IBD. Am J Gastroenterol 2016;111:1682-90. [PMID: 27670602 DOI: 10.1038/ajg.2016.441] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
56 Edlund H, Steenholdt C, Ainsworth MA, Goebgen E, Brynskov J, Thomsen OØ, Huisinga W, Kloft C. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. AAPS J 2017;19:223-33. [PMID: 27739011 DOI: 10.1208/s12248-016-9989-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
57 Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F; Portuguese IBD Study Group (GEDII). Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther 2016;44:684-92. [PMID: 27507790 DOI: 10.1111/apt.13757] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]